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Abstract
Introduction Following the start of the World Health
Organization (WHO) Programme for International Drug
Monitoring (PIDM) by 10 member countries in 1968, it took
another 24 years for the first two African countries to join in
1992, by which time the number of member countries in the
PIDM had grown to 33. Whilst pharmacovigilance (PV),
including the submission of individual case safety reports
(ICSR) to VigiBase, the WHO global ICSR database, is
growing inAfrica, no data have been published on the growth
of ICSR reporting fromAfrica and how the features of ICSRs
from Africa compare with the rest of the world (RoW).
Objective The objective of this paper was to provide an
overview of the growth of national PV centres in Africa,
the reporting of ICSRs by African countries, and the fea-
tures of ICSRs from Africa, and to compare ICSRs from
Africa with the RoW.
Methods The search and analysis interface of
VigiBase—VigiLyze—was used to characterise ICSRs
submitted by African countries and the RoW. The distri-
bution of ICSRs by African countries was listed and
characterised by anatomic therapeutic chemical (ATC)
code, Medical Dictionary for Regulatory Activities
(MedDRA) system organ class (SOC) classification, and
patient age and sex. The case-defining features of ICSRs
between Africa and the RoW were also compared.
Results The number of African countries in the PIDM
increased from 2 in 1992 to 35 at the end of September 2015,
and African PIDM members have cumulatively submitted
103,499 ICSRs (0.88 % of global ICSRs) to VigiBase. The
main class of products in African ICSRs are nucleoside and
nucleotide reverse transcriptase inhibitors (14.04 %), non-
nucleoside reverse transcriptase inhibitors (9.09 %), antivi-
rals for the treatment of HIV infections (5.50 %), combina-
tions of sulfonamides and trimethoprim (2.98 %) and
angiotensin-converting enzyme (ACE) inhibitors (2.42 %).
Themain product classes implicated in ICSRs from the RoW
are tumour necrosis factor-a (TNFa) inhibitors (5.29 %),
topical nonsteroidal anti-inflammatory preparations
(2.26 %), selective immunosuppressants (2.08 %), selective
serotonin reuptake inhibitors (2.04 %) and HMG CoA
reductase inhibitors (1.85 %). Themain SOCs reported from
Africa versus the RoW include skin and subcutaneous tissue
disorders (31.14 % vs. 19.58 %), general disorders and
administration site conditions (20.91 % vs. 30.49 %) and
nervous system disorders (17.48 % vs. 19.13 %). The
18–44 years age group dominated ICSRs fromAfrica, while
the 45–64 years age group dominated the RoW. Identical
proportions of females (57 % Africa and the RoW) and
males (37 % Africa and the RoW) were represented.
Conclusions As at the end of September 2015, 35 of 54
African countries were Full Member countries of the PIDM.
Although the number of ICSRs from Africa has increased
substantially, ICSRs from Africa still make up\1 % of the
global total in VigiBase. The features of ICSRs fromAfrica
differ to those from the RoW in relation to the classes of
products aswell as age group of patients affected. The gender
of patients represented in these ICSRs are identical.
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Key Points
As at the end of September 2015, 35 African
countries were Full Members of the WHO
Programme for International Drug Monitoring.
The 35 countries from Africa have submitted
103,499 (0.88 %) of the global total of 11,824,804
ICSRs in VigiBase submitted by all 122 members
of the PIDM.
ICSRs from Africa differ from the rest of the world
in relation to the classes of products implicated and
the age of patients.
1 Introduction
Pharmacovigilance (PV) is a relatively new science and
public health activity in most African countries compared
with industrialised countries. Before the year 2000, PV was
not a priority in Africa due to several factors, including
poor legislation for medicines regulation, lack of access to
medicines and health commodities, weak and uncoordi-
nated supply chains for medical products, lack of knowl-
edge and awareness of PV, and lack of financial, human
and technical resources for PV [1–3]. Access to medicines
in Africa for managing priority communicable diseases
such as HIV/AIDS, malaria and tuberculosis has increased
since 2000 due to concerted global efforts. In addition, the
emerging middle class are able to pay out of pocket for
their medical care, especially in relation to noncommuni-
cable diseases. The increased access to medicines and
health commodities has shifted the national development
agenda towards safe and cost effective use of these prod-
ucts and the establishment of surveillance systems for their
safety, effectiveness and quality. National PV systems are
therefore now beginning to emerge in Africa.
Globally, the existence of formal national PV systems is
indicated by participation in the WHO Programme for
International Drug Monitoring (PIDM). Membership of the
PIDM is based on the existence of a designated national PV
centre, a spontaneous adverse drug reaction (ADR)
reporting system, and the demonstration of technical
competence in managing individual case safety reports
(ICSRs) by submitting at least 20 ICSRs to the global ICSR
database, VigiBase, maintained by the Uppsala Moni-
toring Centre (UMC), Sweden, on behalf of the World
Health Organization (WHO) [http://who-umc.org/graphics/
24730.pdf]. The PIDM started with 10 members in 1968
following the thalidomide tragedy, and as of September
2015 had 122 Full Member countries, with 29 Associate
Members awaiting full membership while compatibility
between their national format and the international
reporting formats is being established. ICSR reporting to
VigiBase is a useful indicator to measure and compare the
national PV activity of countries, but it is important to
highlight that PV is not just about spontaneous reporting
and ICSR collection and submission; it involves several
other surveillance, clinical and product quality assessment
activities, including active PV and pharmacoepidemiolog-
ical studies, medication error monitoring and the detection
of products with compromised pharmaceutical integrity,
including counterfeit and substandard medicines.
Although the PIDM started in 1968, the first African
countries joined in 1992, and by 30 September 2015 a total
of 35 of 54 African countries were Full Members of the
PIDM. As yet, no comprehensive data have been published
on PV, including ICSR reporting in Africa. A recent article
by Isah et al. [3] provided a broad overview of the specific
features and challenges of PV in Africa and identified the
following constraints: weak human and material resources,
poor training, irrational use of medicines, circulation of
counterfeit medicines, high consumption of herbal
medicines and weak pharmaceutical sector regulation. In
terms of ICSR reporting in Africa, Berhe et al. recently [4]
examined the data in VigiBase and noticed important
differences in adverse drug reaction (ADR) reports for
cardiometabolic drugs between Africa and the rest of the
world (RoW). In particular, they noted differences in the
age groups of patients, as well as higher reporting of ADRs
to angiotensin-converting enzyme (ACE) inhibitors in
African ICSRs compared with the RoW. The reasons
behind such differences are important to ascertain as they
may have implications for product and patient safety;
however, the paucity of publications on PV in Africa
makes this difficult. Researchers are therefore focusing on
assessing the PV infrastructure in low- and middle-income
countries [5] and how PV is being undertaken in important
public health programmes such as malaria [6], HIV [7] and
tuberculosis [8].
In view of the increasing number of African countries
joining the PIDM and submitting data to VigiBase, there
is a need to understand the features of PV in Africa,
including the main ICSR reporting countries, the number
and types of ICSRs being submitted to the PIDM, the
classes of products implicated in these ICSRs and the types
of events reported. This work was therefore undertaken to
provide information on the current PV situation in Africa,
specifically ICSR reporting in Africa. Its main goal was to
provide an overview of reporting activities in Africa and to
compare the characteristics of ICSRs from Africa with
those from the RoW. This will provide needed data to
336 H. H. Ampadu et al.
evaluate the progress of PV in Africa and give the WHO,
national governments, the pharmaceutical industry and
funding organisations a picture of PV in Africa.
2 Objectives
The objectives of this work were to characterise ICSR
reporting activities in Africa and to compare them with the
RoW by (i) documenting the development of PV in Africa
in terms of countries joining the WHO PIDM; (ii) assessing
the reporting of ICSRs to VigiBase by national PV cen-
tres in Africa and identifying the top reporting countries;
(iii) determining the main product classes, the main ADRs
and the demographic features of African ICSRs and com-
paring these with the RoW.
3 Methods
3.1 Data Source
The data source utilised in this quantitative study was
VigiBase, the global ICSR database [9]. VigiBase con-
tains more than 11 million individual case reports of sus-
pected ADRs submitted since 1968 by the 122 member
countries of the WHO Programme. It represents the official
and most authoritative data source for ICSR reporting
globally. VigiBase contains ICSR data on conven-
tional medicines and traditional medicines (herbals), as
well as biological products and vaccines.
3.2 Data Analysis
Quantitative data analysis was undertaken on the number
of ICSRs submitted by each African country, as well as the
types of products and ADRs in these ICSRs. These data
were extracted from VigiBase. Similar analysis was also
undertaken for the RoW. ICSRs from Swaziland, who
became members in 2015, are not included in the cumu-
lative counts since they were entered closer to the data
analysis cutoff date (30 September 2015) and are yet to be
incorporated into the analysis section of VigiBase. The
analysis was performed by using the search and analysis
interface of VigiBase, known as VigiLyze, and Micro-
soft SQL queries. Using the query interface with predefined
filters, data were pulled on reporting statistics, substances
or products and ICSRs in a line listing report output. These
queries were then saved and the output exported to
Microsoft ExcelTM (Microsoft Corporation, Redmond,
WA, USA). The year of joining the WHO Programme as
Full Members by individual countries was obtained from
the website of the WHO PIDM, the UMC (http://www.
who-umc.org), and the population of each country per year
was obtained from the United Nations (http://www.unfpa.
org/swop). The population for each year was summed from
the year they joined the programme, in order to obtain the
cumulative population, which was then used for the cal-
culations below.
The ICSR data were normalised to take into account the
length of time a country has been in the PIDM, as well as
the population size, by expressing the ICSRs as number of
reports per million person-years. In order to know the main
product classes implicated in ICSRs, all products reported
as suspected of causing a reaction were aggregated on the
fourth-level ATC code, and the number of times a product
class was reported was counted. Combination products, by
definition, ended up being counted in terms of their indi-
vidual components so the number of individual active
substances and ATC codes may be more than the number
of products. Since a few active ingredients have more than
one ATC code, the total number of product classes
expressed may be slightly higher than the actual number of
classes submitted in the submitted ICSRs but this is
unavoidable. The ADRs in the ICSRs were identified by
aggregating coded ADRs in each ICSR using the Medical
Dictionary for Regulatory Activities (MedDRA) system
organ class (SOC) classification. The age and gender of
patients in each ICSR were extracted and aggregated for
both Africa and the RoW.
4 Results
4.1 Growth of National Pharmacovigilance (PV)
Centres and Reporting of ICSRs in Africa
The 35 African countries who are Full Members of the
PIDM, their year of joining and the number of reports
(ICSRs) they have submitted since joining the PIDM are
shown in Table 1. Morocco and South Africa were the first
to join in 1992, followed by Tanzania and Tunisia in 1993
and Zimbabwe in 1998. Ten other African countries joined
the PIDM from 2000 to 2008, after which there was a sharp
increase in membership, with 18 countries joining the
PIDM in the 5-year period from 2010 to 2015.
Reporting of ICSRs from Africa is extremely low
compared with the RoW, with the cumulative number of
ICSRs from Africa to VigiBase standing at 103,499
ICSRs, which is equivalent to 0.88 % of the global total
number of 11,824,804 ICSRs in VigiBase at 30 Septem-
ber 2015. The main ICSR reporting countries in Africa in
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terms of cumulative data in VigiBase include South
Africa, Morocco, Nigeria, Egypt and Kenya (Table 2).
South Africa, Morocco and Nigeria alone account for more
than half of the African ICSRs in VigiBase. When the
ICSRs are expressed per million person-years (Table 1),
which normalises ICSRs to take into account population
size as well as the length of time a country has been in the
PIDM, the top countries included Cape Verde, Namibia,
Eritrea, Kenya, Tunisia, South Africa and Morocco.
4.2 Product Classes Implicated in Individual Case
Safety Reports (ICSRs) from Africa
and the Rest of the World (RoW)
The main product classes implicated in ICSRs from Africa
are shown in Table 3, which is dominated by classes of
products for treating HIV/AIDS, namely nucleoside and
nucleotide reverse transcriptase inhibitors (14.04 %), non-
nucleoside reverse transcriptase inhibitors (9.09 %), and
Table 1 Full members of the
Programme for International
Drug Monitoring in Africa
Country Year of joining No. of ICSRs to 2015 No. of ICSRs per million
person yearsa
Angola 2013 239 5.48
Benin 2011 29 0.71
Botswana 2009 103 8.60
Burkina Faso 2010 76 0.92
Cameroon 2010 46 0.42
Cape Verde 2012 247 165.67
Congo, the Democratic Republic of 2010 5558 16.90
Coˆte d’Ivoire 2010 28 0.28
Egypt 2002 8474 8.62
Eritrea 2012 1982 104.31
Ethiopia 2008 803 1.28
Ghana 2001 2900 9.07
Guinea 2013 31 1.30
Kenya 2010 8440 39.07
Liberia 2013 42 4.83
Madagascar 2009 1087 8.23
Mali 2011 80 1.33
Mauritius 2014 39 31.22
Morocco 1992 17,231 25.38
Mozambique 2005 797 3.36
Namibia 2009 1604 119.25
Niger 2012 39 0.72
Nigeria 2005 10,590 6.70
Rwanda 2013 29 1.21
Senegal 2009 181 2.44
Sierra Leone 2008 1272 30.97
South Africa 1992 28,609 27.22
Sudan 2009 38 0.20
Swaziland 2015 27 19.02
Tanzania, United Republic of 1993 1360 1.68
Togo 2008 311 6.86
Tunisia 1993 6990 32.14
Uganda 2008 1871 7.59
Zambia 2010 218 3.09
Zimbabwe 1998 2155 9.77
ICSRs individual case safety reports
a Data from VigiBase to 30 September 2015. Cumulative population to 2014 was used as 2015 data were
not yet available
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antivirals for treatment of HIV infections (5.50 %). Others
include combinations of sulfonamides and trimethoprim,
including derivatives (2.98 %), ACE inhibitors, plain
(2.42 %), antibiotics (2.26 %), meningococcal vaccines
(2.23 %), interferons (2.06 %) and combination products
for tuberculosis (1.87 %). In contrast to African ICSRs,
there is no single dominant product class in RoW reports
(Table 4). The classes of products commonly reported in
ICSRs from the RoW (Table 4) include tumour necrosis
factor-a (TNFa) inhibitors (5.29 %), anti-inflammatory
preparations, nonsteroids for topical use (2.26 %), selective
immunosuppresants (2.08 %), selective serotonin reuptake
inhibitors (2.04 %), and HMG CoA reductase inhibitors
(1.85 %).
4.3 Adverse Drug Reactions (ADRs) in ICSRs
from Africa and the RoW
In SOC classification, African ICSRs are dominated by
reports of skin and subcutaneous tissue disorders
(31.14 %), general disorders and administration site con-
ditions (20.91 %), nervous system disorders (17.48 %) and
gastrointestinal disorders (16.10 %), as shown in Table 5.
These are followed by respiratory, thoracic and mediastinal
disorders (5.71 %), investigations (5.07 %), blood and
lymphatic system disorders (5.04 %), psychiatric disorders
(4.72 %), musculoskeletal and connective tissue disorders
(4.36 %) and infections and infestations (3.78 %). The
main ADRs in the RoW reports (Table 6) are not dissimilar
from those reported in Africa and include general disorders
and administration site conditions (30.49 %), skin and
connective tissue disorders (19.58 %), nervous system
disorders (19.13 %), and gastrointestinal disorders
(17.86 %).
4.4 Patient Characteristics: Africa vs. the RoW
The dominant age group from Africa was 18–44 years
(39.10 %) compared with the RoW, which is dominated
by an older age group of 45–64 years (24.13 %) (Fig. 1).
A significant proportion of reports from both Africa
(16.18 %) and the RoW (26.00 %) failed to mention the
age group of those affected, highlighting the incom-
pleteness of a good number of ICSRs submitted to
VigiBase. The gender of patients in African and RoW
ICSRs are identical for females (57 % Africa vs. 57 %
RoW) and males (37 % Africa vs. 37 % RoW). Six per-
cent of reports from both Africa and the RoW did not
specify the gender.
Table 2 Main African reporting countries

















ICSRs individual case safety reports
a Total ICSRs from all African countries to 30 September 2015
(excluding Swaziland, n = 27) was 103,499
Table 3 Top 10 product classes
in African reports vs. RoW
reports
ATC code Africa (%)a RoW (%)b
J05AF—nucleoside and nucleotide reverse transcriptase inhibitors 14,530 (14.04) 44,055 (0.38)
J05AG—non-nucleoside reverse transcriptase inhibitors 9407 (9.09) 26,107 (0.22)
J05AR—antivirals for the treatment of HIV infections, combinations 5692 (5.50) 34,927 (0.30)
J01EE—combinations of sulfonamides and trimethoprim, incl.
derivatives
3082 (2.98) 81,206 (0.69)
C09AA—ACE inhibitors, plain 2503 (2.42) 154,176 (1.32)
S01AA—antibiotics 2340 (2.26) 179,635 (1.53)
J07AH—meningococcal vaccines 2308 (2.23) 48,480 (0.41)
L03AB—interferons 2130 (2.06) 211,098 (1.80)
J04AM—combinations of drugs for treatment of tuberculosis 1933 (1.87) 7043 (0.06)
D06AX—other antibiotics for topical use 1855 (1.79) 103,228 (0.88)
RoW rest of the world, ATC anatomic therapeutic chemical, ACE angiotensin-converting enzyme, ICSRs
individual case safety reports
a Percentage includes all African ICSRs (n = 103,499) in VigiBase (excluding Swaziland, n = 27)
b Percentage of all RoW ICSRs (n = 11,721,305) in VigiBase
Comparison of ICSR Characteristics between Africa and the RoW 339
Table 4 Top 10 product classes
in RoW reports vs. African
reports
ATC code RoW (%)a Africa (%)b
L04AB—tumour necrosis factor alpha inhibitors 619,737 (5.29) 939 (0.91)
M02AA—antiinflammatory preparations, non-steroids for topical use 265,138 (2.26) 1350 (1.30)
L04AA—selective immunosuppressants 243,382 (2.08) 238 (0.23)
N06AB—selective serotonin reuptake inhibitors 238,611 (2.04) 718 (0.69)
C10AA—HMG CoA reductase inhibitors 217,302 (1.85) 936 (0.9)
M01AE—propionic acid derivatives 214,595 (1.83) 738 (0.71)
L03AB—interferons 211,098 (1.80) 2130 (2.06)
N05AH—diazepines, oxazepines, thiazepines and oxepines 205,773 (1.76) 650 (0.63)
N06AX—other antidepressants 201,461 (1.72) 1398 (1.35)
N03AX—other antiepileptics 187,813 (1.60) 959 (0.93)
RoW rest of the world, ATC anatomic therapeutic chemical, ICSRs individual case safety reports
a Percentage of all RoW ICSRs (n = 11,721,305) in VigiBase
b Percentage of all African ICSRs (n = 103,499) in VigiBase (excluding Swaziland, n = 27)
Table 5 Top 10 SOCs in
African reports vs. RoW reports
SOC Africa (%)a RoW (%)b
Skin and subcutaneous tissue disorders 32,225 (31.14) 2,295,539 (19.58)
General disorders and administration site conditions 21,642 (20.91) 3,574,082 (30.49)
Nervous system disorders 18,094 (17.48) 2,242,378 (19.13)
Gastrointestinal disorders 16,662 (16.10) 2,093,534 (17.86)
Respiratory, thoracic and mediastinal disorders 5912 (5.71) 1,046,599 (8.93)
Investigations 5245 (5.07) 1,080,507 (9.22)
Blood and lymphatic system disorders 5219 (5.04) 523,173 (4.46)
Psychiatric disorders 4890 (4.72) 1,042,390 (8.89)
Musculoskeletal and connective tissue disorders 4512 (4.36) 905,026 (7.72)
Infections and infestations 3912 (3.78) 846,842 (7.22)
SOC system organ class, RoW rest of the world, ICSRs individual case safety reports
a Percentage of all African ICSRs (n = 103,476) in VigiBase (excluding Swaziland, n = 27)
b Percentage of all RoW ICSRs (n = 11,721,305) in VigiBase
Table 6 Top 10 SOCs in RoW
reports vs. African reports
SOC RoW (%)a Africa (%)b
General disorders and administration site conditions 3,574,082 (30.49) 21,631 (20.91)
Skin and subcutaneous tissue disorders 2,295,539 (19.58) 32,225 (31.14)
Nervous system disorders 2,242,378 (19.13) 18,094 (17.48)
Gastrointestinal disorders 2,093,534 (17.86) 16,662 (16.10)
Investigations 1,080,507 (9.22) 5245 (5.07)
Respiratory, thoracic and mediastinal disorders 1,046,599 (8.93) 5912 (5.71)
Psychiatric disorders 1,042,390 (8.89) 4890 (4.72)
Injury, poisoning and procedural complications 946,308 (8.07) 3008 (2.91)
Musculoskeletal and connective tissue disorders 905,026 (7.72) 4512 (4.36)
Infections and infestations 846,842 (7.22) 3912 (3.78)
SOC system organ class, RoW rest of the world, ICSRs individual case safety reports
a Percentage of all RoW ICSRs (n = 11,721,305) in VigiBase
b Percentage of all African ICSRs (n = 103,499) in VigiBase (excluding Swaziland, n = 27)
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5 Discussion
5.1 Growth of PV in Africa and Features of ICSR
Reporting to VigiBase
Africa was a late comer to global PV, with the first coun-
tries becoming involved 24 years after the PIDM started.
Whilst the 24-year gap raises troubling questions as to the
types of vaccine and medicine safety incidents that may
have gone unrecorded, the fact remains that in 2015 there
are still 21 African countries who are not members of the
PIDM. The growth of African PV in terms of countries
joining the PIDM started more as a trickle than a concerted
continental effort. From 1992 to 2000, there were only five
African members of the PIDM before membership gath-
ered pace in the new millennium. Why did it take so long
for African countries to start joining the PIDM and what
were the factors underlying this movement? The factors are
many and diverse and some authors have mentioned
important health system obstacles to PV growth in Africa,
including weak overall national health infrastructure and
systems, poor understanding of PV, lack of PV in the
formal curriculum and low interest by healthcare profes-
sionals [10–14]. The steady growth in PIDM membership
from 2000 could be due to several factors. The Millennium
Development Goals and its focus on health improvement,
as well as prevention of infant and maternal mortality,
firmly shifted the development agenda to healthcare
delivery and health system strengthening in poor countries.
The establishment of the Global Fund against HIV/AIDS,
Tuberculosis and Malaria (Global Fund), as well as other
important global health initiatives (US President’s Emer-
gency Plan for Aids Relief [PEPFAR], US President’s
Malaria Initiative, the Bill and Melinda Gates Foundation,
etc.) brought in huge financial resources that enhanced
access to medicines [15]. With increased access to
medicines, the need to monitor their safety became obvi-
ous. The Global Fund, for instance, insisted on safety
monitoring of all its products as a key requirement for grant
recipients as early as 2002, although research indicates that
this was only partially adhered to [16], with improved
adherence occurring only after the Fund included a
mandatory field relating to PV on all grant application
forms in 2010. The WHO in Geneva, as well as the UMC
in Sweden and the WHO Collaborating Centre for PV in
Rabat, Morocco, undertook a focused approach on PV
capacity building in Africa, with the UMC alone training
100 Africans since 1993 in its annual PV course. The
United States Agency for International Development
(USAID), working in particular with Management Sci-
ences for Health (MSH), also supported PV activities in
Africa. However, the most direct impact on countries
joining the PIDM comes from the establishment of an
African hub to lead PV development on the continent. In
June 2009, the UMC established an African office (UMC–
Africa) with dedicated funding, while the WHO designated
the University of Ghana (October 2009) as a WHO Col-
laborating Centre for Advocacy and Training in Pharma-
covigilance (WHO–CC), working hand-in-hand with
UMC–Africa. The African hub (WHO–CC, UMC–Africa)
undertook advocacy, country visits, in-country training and
capacity building in several countries, culminating in most
of them becoming full members of the PIDM. The rapid
increase in African countries joining the PIDM since 2009
is due mainly to this focused continental effort.
In relation to ICSR reporting to VigiBase, the data
suggest that nearly one-third of the countries in Africa
submit enough data (at least 20 ICSRs) to gain membership
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September 2015. RoW rest of
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of the PIDM, after which there is a pause—currently 10
countries have submitted less than 100 ICSRs to
VigiBase. Poor reporting of ICSRs hinders signal gener-
ation. However, for sustainable PV systems, reporting and
signal generation needs to be embedded in wider health
system-related policies and infrastructures, and this is
currently not the case in many countries. For instance, a
2009 survey of PV in 46 sub-Saharan African countries
[17] showed that less than half have a national policy that
covers PV and 72 % do not have a legal mandate to
monitor medicine-related adverse events. Furthermore,
only 39 % have national PV guidelines or a national safety
advisory committee, and only 28 % have a platform or
strategy to coordinate PV at the national level. While
African membership of the PIDM has increased, the poor
reporting of ICSRs is an indication that health system
issues have not been adequately dealt with. Another survey
might be necessary to identify appropriate interventions for
improving ICSR reporting in Africa. Africa’s population of
over 1 billion (15 % of the global total) and its healthcare
features (high number of infectious diseases, e.g. HIV/
AIDS, tuberculosis, malaria, etc., and increasing incidence
of noncommunicable diseases) means that the population is
exposed to a high number of medical products, which
should theoretically translate to high ICSR reporting. The
low number of ICSRs (\1 % of ICSRs in VigiBase) is an
indication of weak PV activity, especially when one con-
siders the fact that several of the priority diseases in Africa
are managed through formal, reasonably well-funded
public health programmes that administer large numbers of
medicines to millions of individuals annually. The rela-
tively high ICSR reporting countries in Africa appear to be
those with an active pharmaceutical industry presence or
strong public health programmes.
5.2 Classes of Products Implicated in ICSRs
from Africa
The main product classes implicated in ICSRs are anti-
infectives, notably antiretrovirals and antibiotics. The
domination of HIV/AIDS products in African ICSRs is
perhaps not surprising considering the high burden of HIV/
AIDS on the continent. With well-funded programmes
providing access to antiretrovirals, it is expected that there
would be more ICSRs on these products since healthcare
workers in these programmes tend to be trained in PV.
Indeed, most published PV studies from Africa tend to be
on the safety of antiretrovirals [18, 19]. The relatively high
number of reports to ACE inhibitors may be an indication
of the changing morbidity patterns on the continent with a
steeply increasing burden of communicable diseases, in
addition to the persisting dominance of noncommunicable
diseases as noted and reported by the WHO, the UN and
several other players [20–22]. It is interesting to note that
the article by Berhe et al. [4], which examined ADRs to
cardiometabolic drugs, found a disproportionately higher
reporting of ADRs to ACE inhibitors when comparing
ICSRs from sub-Saharan Africa with the RoW (36 % vs.
14 %). Differences such as these underscore the impor-
tance of improving ICSR reporting from Africa in order to
improve the chances of detecting any African-specific
safety issues. The presence of the meningococcal vaccine
among the top product classes implicated in African ICSRs
may be due to the recent large-scale roll out of the
meningococcal vaccine across West Africa in response to
outbreaks. This particular programme was accompanied by
a concerted PV effort. The vaccines that are widely used in
national childhood immunisation programmes in Africa did
not feature among the main product categories reported, a
strong suggestion that systems for monitoring adverse
events following immunization may be absent or that
national expanded programmes on immunization do not
submit safety data to national PV centres and to VigiBase.
5.3 Main ADRs in African ICSRs
The main SOC reported in African ICSRs relate to the
expected ADRs of the product classes in African ICSRs.
General disorders, skin and appendage disorders and ner-
vous system disorders are among the most frequent and
easily identifiable event types reported to antiretrovirals
and antibiotics. The presence of ‘investigations’ among the
ADRs in African ICSRs could be due to the public health
programmes which provide routine laboratory investiga-
tions as part of standard care since laboratory investiga-
tions are rarely carried out in routine care in Africa due to
cost considerations. Representing the ADRs reported as
SOCs does not provide the ability to distinguish the indi-
vidual ADRs (‘Preferred Terms’, or PTs) reported. Whilst
this was not the focus of the current work, the article by
Berhe et al. [4] revealed higher reporting of certain ADRs
when expressed as PTs (e.g. lip swelling, cough, angioe-
dema) and little of others (e.g. death, myocardial infarction,
congestive cardiac failure) when data from Africa are
compared with the RoW, an indication once again of the
ability of ICSRs to reveal safety differences between
Africa and the RoW.
5.4 Features of ICSRs: Africa vs. the RoW
There is a difference in the product classes implicated in
ICSRs from Africa compared with the RoW. Several fac-
tors could account for this, including differences in disease
patterns and prescriptions, differences in PV systems and
ADR reporting, and differences in health systems and
health literacy, amongst others. These issues are impossible
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to determine from analyses of VigiBase data. However,
an extremely important fact that VigiBase reveals is that
reporting from Africa is extremely low, even for diseases
that are more prevalent in Africa. For instance, there were
three- to sixfold more ICSRs to nucleoside reverse tran-
scriptase inhibitors, non-nucleotide reverse transcriptase
inhibitors and combination antivirals in the RoW than in
Africa, even though many more millions of these products
are used in Africa than in the RoW. A similar situation
occurred in relation to the reporting of ICSRs to anti-
malarials, as noted by Kuemmerle et al. [6]. ICSRs from
the RoW were not dominated by any one class of products,
an indication of a PV system that looks at all prevailing
conditions and medicines used in their management rather
than only products for ‘public health programmes’. Thus,
while antiretrovirals form the top three product classes in
African ICSRs and account for more than 30 % of African
reports, the three main product classes from the RoW are
TNFa inhibitors, topical nonsteroidal anti-inflammatory
agents and selective immunosuppresants. These three
product classes account for 9.63 % of all RoW ICSRs. The
only product class that was among the top 10 from both
Africa and the RoW are interferons (2130 vs. 211,098
ICSRs), an interesting observation considering their usage
in a wide range of conditions, including HIV/AIDS-related
Kaposi’s sarcoma, leukaemia, hepatitis B, and multiple
sclerosis, amongst others. HMG CoA reductase inhibitors
(statins), antidepressants, nonsteroidal anti-inflammatory
drugs and benzodiazepines are poorly represented in
African ICSRs. This is not due to the absence of conditions
such as hypercholesterolemia, depression, inflammation,
insomnia and epilepsy in Africa. Rather, it seems to reflect
poor reporting of ICSRs and/or poor prescriptions for
products to deal with these conditions, or both. For
instance, the work by Berhe et al. [4] found poor reporting
of ICSRs to statins, with all but two ICSRs to statins
coming from one country (South Africa), which Berhe
et al. inferred to probably be due to a focused PV activity
by the manufacturer. The main product class implicated in
the RoW ICSRs are TNFa inhibitors (including mono-
clonal antibodies), which are indicated for a wide range of
serious life-threatening conditions and are widely used.
Several are marketed with ‘black-box’ warnings requiring
reporting of all events to national regulatory agencies.
TNFa inhibitors are unlikely to be used by large numbers
of people in Africa due to their high cost, and this may
explain why they do not feature among the top product
classes in African ICSRs.
The only difference in the demography of patients in
ICSRs from Africa and the RoW is in relation to age. The
subgroup analysis of cardiometabolic drugs undertaken by
Berhe et al. [4] found the same difference, which is not
surprising considering that the population in Africa is
relatively younger compared with the RoW. Females
dominate ICSRs in both Africa and the RoW.
The present study has shown that PV in Africa is
growing in terms of the number of countries joining the
PIDM, as well as the number of ICSRs being submitted.
African reports are different from the RoW, offering the
possibility of identifying important safety signals, as
already mentioned by others [23]. However, the absolute
numbers of ICSRs in VigiBase are extremely low. The
increasing promotion of other PV methods, including
targeted spontaneous reporting and cohort event moni-
toring [24], could strengthen PV in Africa, while educa-
tional interventions and the use of the recent WHO–
International Society of Pharmacovigilance (ISoP) PV
curriculum [25] should support standardised PV educa-
tion. Both of these would both contribute toward
improved ICSR reporting from Africa. The era of coun-
tries submitting just the sufficient number of ICSRs to
become members of the PIDM would then be a thing of
the past, especially if countries could use PV assessment
tools such as the WHO PV Indicator and the MSH
Indicator-based Pharmacovigilance Assessment Tool
(IPAT) to evaluate their own systems and target inter-
ventions as appropriate.
6 Limitations
This study was a review only of the data submitted by
national PV Centres to VigiBase, which may be a tiny
fraction of the overall ICSRs in-country. Differences in
health systems, prescriptions and disease patterns could
also account for several of the differences observed
between Africa and the RoW. Unpublished evidence
gathered during PV country support missions in Africa
suggests that the capacity for data management, including
ICSR submission to VigiBase, is weak; several countries
had an appreciable quantity of data stored in various ways
(boxes, spreadsheets, etc.), and yet to be submitted to
VigiBase. A significant proportion of ICSRs that are filled
out by healthcare professionals remain with national PV
centres and are not submitted to VigiBase. Each ICSR
used in the analyses in this study could contain more than
one ADR, hence the number of SOCs may be more than the
number of ICSRs. The counting of combination products
and products that are used concurrently (e.g. the use of
highly active antiretroviral therapy) may lead to some
products being over-represented in the count of products
implicated in ICSRs. Finally, the data were analysed as
present in VigiBase, meaning they contain the essential
basic features of reporting (identified patient, product,
ADR and reporter) without any assessment of causality or
evaluation of the quality of the report.
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7 Conclusions
PV in Africa is in its developing stages, with low numbers
of ICSRs reported to VigiBase. Several countries from
Africa have joined the PIDM over the past few years but
more than one-third of African countries are still not
members of the PIDM. The characteristics of ICSRs from
Africa are quite different from those of the RoW in terms
of products and types of ADRs reported. African ICSRs are
dominated by products for infectious diseases, including
HIV/AIDS and antibiotics, while ICSRs from the RoW are
mainly in relation to the following classes of products,
namely TNFa inhibitors, topical nonsteroidal anti-inflam-
matory drugs, immunosuppresants, selective serotonin
reuptake inhibitors and statins. The dominant age groups in
reports from Africa and the RoW also differ, while the
gender of patients are nearly identical. With further
developments and improvements in PV in Africa, the
reporting and submission of ICSRs of good quality to
VigiBase is expected to grow. This will permit signal
detection and the utilisation of other proactive methods for
safety surveillance of medicines, vaccines and all other
medical products to improve patient safety and public
health.
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